Ceftazidime prescription and antibiotic resistance patterns in a tertiary care hospital Authors: Banan M Aiesh, Shama Amoudi, Leena Bassalat, Abeer Yousef, Dania Abuhalima, Adham Abutaha, Samah W Al-Jabi, Ali Sabateen, Sa’ed H Zyoud Published: 2025 ABSTRACT AbstractCeftazidime, a third-generation cephalosporin, is effective for treating infections caused by gram-negative bacteria. However, increasing antibiotic resistance, particularly in multidrug-resistant gram-negative bacilli, complicates treatment decisions and patient outcomes. This study aimed to assess the clinical epidemiology and characteristics of patients treated with intravenous ceftazidime and clarify the drug resistance patterns of the isolated pathogens. A retrospective cross-sectional study was conducted at a tertiary care center in the West Bank between June 2021 and June 2023. The study included 558 inpatients across various departments. The data collected included patient demographics, comorbidities, indications for ceftazidime use, dosage regimens, treatment outcomes, and microbiological findings. The demographic and clinical profiles of 558 patients revealed a diverse age distribution, with 57.3% aged 19–65 years. Males constituted 53.2% of the sample. Hematological malignancies (55%) and cardiovascular diseases (32.1%) were the predominant comorbidities. Ceftazidime was predominantly used in oncology settings (68.5%), with neutropenic fever (39.6%) and pneumonia (35.7%) being the most common indications. Discharge was the most common outcome (91.6%), whereas antibiotic interventions, including upgrading therapy (19.4%), were reported. Notably, Escherichia coli was the most isolated pathogen (36.1%), with 47.2% of the isolates demonstrating resistance to ceftazidime. Solid malignancies, diabetes mellitus, and liver disease were significantly associated with poorer outcomes (p < 0.05). Neutropenic fever was linked to better outcomes, whereas pneumonia and sepsis were strongly associated with death. A total of 87.4% of patients developed sepsis or septic shock during treatment (p < 0.05). This study investigated the use of ceftazidime, especially in oncology settings, in a tertiary care hospital. The increasing resistance rate to ceftazidime—particularly among Escherichia coli and Klebsiella pneumoniae—poses a major challenge for empirical therapy and underscores the urgent need for antimicrobial stewardship in resource-limited settings. Patient age, comorbidities, and infection type significantly influence outcomes, underscoring the need for careful risk stratification. These findings highlight the importance of locally adapted treatment guidelines, routine microbiological surveillance, and further research to optimize antibiotic use and improve patient outcomes.Keywords: Ceftazidime, Oncology, Antibiotic resistance, Third-generation cephalosporins, Empirical therapy, Neutropenic feverSubject terms: Microbiology, Health care, Medical research Background Antibiotic resistance has emerged as one of the most pressing global health threats, compromising the effectiveness of many first-line antibiotics1. The World Health Organization (WHO) has declared antimicrobial resistance (AMR) a global priority, particularly with the rise of multidrug-resistant gram-negative bacteria2. Ceftazidime, a widely used third-generation cephalosporin, is often employed to treat hospital-acquired infections caused by Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. However, its efficacy is being undermined by increasing rates of resistance, especially in low- and middle-income countries (LMICs), where empirical therapy is common and antibiotic stewardship programs (ASPs) may be limited3. Antimicrobial resistance in gram-negative pathogens is often mediated by extended-spectrum beta-lactamases (ESBLs) and carbapenemases, which inactivate β-lactam antibiotics, including third-generation cephalosporins4. A 2024 study from Lebanon reported ceftazidime resistance in more than 60% of Acinetobacter baumannii isolates5. In Saudi Arabia and Jordan, Klebsiella pneumoniae and E. coli isolates have shown high levels of ceftazidime and multidrug resistance6,7. In Palestine, recent studies by Rabayah et al.. and Joudeh et al.. reported a rising burden of ESBL-producing organisms among oncology and febrile neutropenia patients8,9. These findings highlight the urgent need to evaluate local resistance patterns and optimize the use of ceftazidime as empirical therapy. This study was designed to address this critical issue by focusing on three main objectives: (1) to determine the rate and patterns of resistance to ceftazidime among hospitalized patients in a tertiary care center in Palestine; (2) to evaluate the frequency and type of antibiotic stewardship interventions (e.g., escalation or de-escalation) related to ceftazidime use; and (3) to assess clinical outcomes, including sepsis, mortality, and potential adverse effects, in patients who received empirical ceftazidime therapy. This issue is particularly relevant in the Palestinian context, where healthcare providers face daily challenges related to medication shortages, limited access to newer broad-spectrum antibiotics, and delays in diagnostic testing. Owing to restricted movement, political instability, and import constraints, many hospitals rely heavily on empirical treatment protocols using available agents such as ceftazidime. The lack of local antibiogram data and the underdevelopment of ASPs further complicate antibiotic selection. These contextual factors underscore the urgency of examining local resistance trends and evaluating the clinical appropriateness of commonly prescribed antibiotics. The current study investigated ceftazidime prescription patterns in a well-known Palestinian hospital. We aimed to determine what indications and infections it is prescribed for and how often it is prescribed. Additionally, we aimed to study the demographic and clinical characteristics of patients managed with ceftazidime, patient outcomes, and microbiological profiles of the isolated pathogens. To the best of our knowledge, this is the first study of its kind in Palestine, and it will help physicians prescribe ceftazidime more effectively. In addition to being the first national evaluation of ceftazidime resistance and prescribing patterns, this study uniquely integrates clinical outcomes, ASP interventions, and microbiological data to provide a comprehensive picture of ceftazidime use in a real-world tertiary care setting. Unlike prior regional studies that have focused mainly on microbiological resistance patterns, our study is the first in Palestine to integrate prescribing patterns, clinical outcomes, ASP interventions, and microbiological data into a single analysis. This holistic approach provides novel insights into how ceftazidime is used in a real-world tertiary setting and its implications for AMR management. Methods Study design and timing This study involved a retrospective cross-sectional analysis of patient records at An-Najah National University Hospital (NNUH), which is a tertiary academic hospital in Palestine that serves complex surgical, solid malignancy and hemato-oncological cases. This institution comprises a total of 135 beds. This research focused on assessing the clinical epidemiology and characteristics of patients who received IV ceftazidime between June 2021 and June 2023. Medical records from June 2021 to June 2023 were analysed for patients who received intravenous ceftazidime. Data from 558 inpatients across various hospital departments were examined, excluding outpatient settings. Study population and sample size All patients of all ages and sexes who received IV ceftazidime in inpatient settings (surgical, medical, pediatric, cardiac, intensive care unit, bone marrow transplant, cardiovascular surgery, or internal) were included. We excluded outpatient settings, hemodialysis center, and patients who received targeted ceftazidime therapy. The sample size for the study was calculated through a predetermined analysis to ensure both adequate statistical power and representativeness. Using the Raosoft sample size calculator, with parameters of a 50% response distribution, a 0.05 margin of error, and a 95% confidence level, we determined that a minimum of 377 patients were needed. To increase the reliability and statistical power of the study, we decided to enrol 558 patients. Primary and secondary outcomes The main aim of this study was to evaluate the prescription pattern of ceftazidime, including the indications for ceftazidime use, duration of therapy, dosage administered, and patient outcomes. However, the secondary goal was to study microbiological profiles, including microbial resistance patterns to ceftazidime, in addition to the occurrence of sepsis or septic shock among patients receiving empirical ceftazidime (the occurrence of sepsis or septic shock was recorded if it developed during hospitalization following ceftazidime administration), along with the length of hospital stay. Data collection and analysis This study can be classified as a descriptive study that involved retrospective analysis of patient records to assess the outcomes and usage patterns of intravenous ceftazidime without implementing a controlled experimental environment. We gathered key variables from existing studies10,11 and compiled them into Excel spreadsheets, using a format similar to that of studies conducted in our settings12–15. The records of patients who received IV ceftazidime were reviewed at each admission, and the data collection form included the following sections: Section 1 included the patient’s age, sex and admission ward. Section 1 included the patient’s age, sex and admission ward. Section 2 included information on comorbidities such as hematological malignancies, cardiovascular disorders, solid malignancies, diabetes mellitus, kidney disease and liver disease. Section 2 included information on comorbidities such as hematological malignancies, cardiovascular disorders, solid malignancies, diabetes mellitus, kidney disease and liver disease. Section 3 describes the different indications for IV ceftazidime use, including neutropenic fever, pneumonia, fever, and sepsis (according to SIRS criteria: body temperature above 38 °C or below 36 °C, heart rate greater than 90 beats per minute, respiratory rate greater than 20 beats per minute or carbon dioxide partial pressure below 4.3 kPa, and neutrophilia above 12000/mm3 or neutropenia below 4000/mm3 with 10% or more nonsegmented peripheral blood neutrophils)16, urinary tract infection, soft tissue infection, bacteremia, intra-abdominal infection, surgical prophylaxis, tonsillitis, meningitis, peritonitis, pharyngitis, acute otitis media, cholangitis, encephalitis, endocarditis, and sinusitis. Additionally, it included patient distribution across hospital wards. Section 3 describes the different indications for IV ceftazidime use, including neutropenic fever, pneumonia, fever, and sepsis (according to SIRS criteria: body temperature above 38 °C or below 36 °C, heart rate greater than 90 beats per minute, respiratory rate greater than 20 beats per minute or carbon dioxide partial pressure below 4.3 kPa, and neutrophilia above 12000/mm3 or neutropenia below 4000/mm3 with 10% or more nonsegmented peripheral blood neutrophils)16, urinary tract infection, soft tissue infection, bacteremia, intra-abdominal infection, surgical prophylaxis, tonsillitis, meningitis, peritonitis, pharyngitis, acute otitis media, cholangitis, encephalitis, endocarditis, and sinusitis. Additionally, it included patient distribution across hospital wards. Section 4 describes the relationship between patient outcomes (discharge versus death) and two key variables: the dosage of ceftazidime (including total daily dose, maximum dose, and minimum dose) and the duration of ceftazidime treatment. Additionally, it provides an overview of the outcome in terms of overall mortality at the current admission (discharged or died) and interventions (stopped, downgraded, or upgraded). In this study, ‘downgrading’ refers to switching from ceftazidime to a narrower-spectrum antibiotic, whereas ‘upgrading’ refers to switching to a broader-spectrum antibiotic on the basis of clinical judgement or microbiological findings. The usual dose of intravenous ceftazidime in our hospital setting is 1–2 g every 8–12 h for adults, with pediatric doses adjusted according to body weight and renal dose adjustment for patients with renal impairment. Section 4 describes the relationship between patient outcomes (discharge versus death) and two key variables: the dosage of ceftazidime (including total daily dose, maximum dose, and minimum dose) and the duration of ceftazidime treatment. Additionally, it provides an overview of the outcome in terms of overall mortality at the current admission (discharged or died) and interventions (stopped, downgraded, or upgraded). In this study, ‘downgrading’ refers to switching from ceftazidime to a narrower-spectrum antibiotic, whereas ‘upgrading’ refers to switching to a broader-spectrum antibiotic on the basis of clinical judgement or microbiological findings. The usual dose of intravenous ceftazidime in our hospital setting is 1–2 g every 8–12 h for adults, with pediatric doses adjusted according to body weight and renal dose adjustment for patients with renal impairment. In Section 5 the source of infection, specific microorganisms isolated from patients receiving IV ceftazidime, the minimum inhibitory concentration (MIC) and sensitivity to ceftazidime were collected. In Section 5 the source of infection, specific microorganisms isolated from patients receiving IV ceftazidime, the minimum inhibitory concentration (MIC) and sensitivity to ceftazidime were collected. Statistical analysis Data were analyzed using IBM SPSS Statistics version 25.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics were applied to summarize patient sociodemographic characteristics, medical history, disease comorbidities, and current admission status. Continuous variables such as age, length of hospital stay, dose, and treatment duration were summarized using either the mean and standard deviation or the median and interquartile range (IQR) on the basis of the distribution of the data. Categorical variables are presented as frequencies and percentages. To evaluate associations between categorical variables, the chi-square test or Fisher’s exact test was applied, with a p value of less than 0.05 considered statistically significant. For data that were not normally distributed, as verified by the Shapiro–Wilk test, the median was used as a more appropriate measure of central tendency. Consequently, the Mann–Whitney test was employed when comparing two groups. Microbiological identification Bacterial identification and antibiotic susceptibility testing were performed via the VITEK® 2 Compact automated system (bioMérieux, Marcy l’Étoile, France). The identification of bacteria was performed with a VITEK® 2 Gram-Negative (GN) identification card. For antibiotic susceptibility testing, AST-N419 cards were used for Pseudomonas and Acinetobacter species, whereas AST-N417 cards were used for various Enterobacterales species. ESBL production and carbapenem resistance were also determined via the VITEK® 2 Compact system. Ethical considerations The study protocol, which involved accessing and utilizing patient clinical data, received approval from the Institutional Review Boards (IRBs) at An-Najah National University (PharmD.Sep.2022/28). Additionally, authorization to access patient files was obtained from An-Najah National University Hospital. Given the retrospective design of the study and the use of anonymized data, the IRB of An-Najah National University waived the requirement for informed consent. All research activities were conducted in accordance with the principles set forth in the Declaration of Helsinki and in compliance with applicable guidelines and regulations. Data confidentiality was strictly maintained, and the information was exclusively used for clinical research purposes. To protect patient privacy, identifiable data were replaced with numerical codes throughout the study. Results Demographics and clinical profile of patients treated with IV Ceftazidime A total of 558 patients were analysed across various age groups and demographic factors. The age distribution revealed that 22.9% were younger than 19 years and that 19.7% were older than 65 years. The sex distribution revealed that 53.2% of the patients were males and that 46.8% were females. Hematological malignancies were present in 55% of the patients, while 32.1% of them had cardiovascular diseases. On the other hand, 28% of them had solid malignancies. The administration of ceftazidime has been observed across various medical departments. The majority of ceftazidime utilization occurred in oncology settings, constituting 68.5% of the cases. Internal medicine accounted for 9.3% of the ceftazidime-treated patients, followed by pediatrics at 8.1%. Detailed demographic data are presented in Table 1. Table 1Demographics and clinical profile of patients treated with IV ceftazidime.VariableN (% of available data)Age (years)Less than 19128 (22.9)19–65320 (57.3)More than 65110 (19.7)GenderMale297 (53.2)Female261 (46.8)Hematological malignancies307(55)Cardiovascular diseases179 (32.1)Solid malignancies156 (28)Diabetes mellitus89 (15.9)Kidney disease68 (12.2)Liver disease31 (5.6)WardN (%)Oncology382(68.5)Internal medicine52(9.3)Pediatrics45 (8.1)Cardiac care unit23 (4.1)Medical intensive care unit23(4.1)Surgical intensive care unit18(3.2)Surgery6 (1.1)Pediatric intensive care unit5 (0.9)Vascular surgery4 (0.7)Total558 (100)* Others: Rheumatoid arthritis, hemophagocytic lymph histiocytosis, Down syndrome, ulcerative colitis, viral infection, respiratory disorder, central nervous system disorder, systemic lupus erythematous, hemorrhoids, gout, anemia and thyroid disorder. Demographics and clinical profile of patients treated with IV ceftazidime. * Others: Rheumatoid arthritis, hemophagocytic lymph histiocytosis, Down syndrome, ulcerative colitis, viral infection, respiratory disorder, central nervous system disorder, systemic lupus erythematous, hemorrhoids, gout, anemia and thyroid disorder. Indications for IV Ceftazidime use Among the patients treated with IV ceftazidime, multiple indications have been reported, resulting in 750 instances, reflecting the overlap in indications for some patients, as shown in Table 2. The most common indication for ceftazidime use was neutropenic fever, which occurred in 39.6% of the patients, followed closely by pneumonia in 35.7% of the patients. Fever, as a standalone indication, was noted in 26% of patients. Table 2Indications for IV Ceftazidime use.IndicationN (%)Neutropenic fever221 (39.6)Pneumonia199 (35.7)Fever145 (26)Sepsis (at baseline)70 (12.5)Urinary tract infection56(10)Soft tissue infection17 (3)Surgical prophylaxis10 (1.8)Bacteremia9 (1.6)Intra-abdominal infectionOthers*8 (1.4)15 (2.7) Total 750 (134.3) *Overlap presented owing to multiple indications for some patients.*Others: Tonsillitis, meningitis, peritonitis, pharyngitis, cholangitis, pancreatitis, and sinusitis. Indications for IV Ceftazidime use. Intra-abdominal infection Others* 8 (1.4) 15 (2.7) *Overlap presented owing to multiple indications for some patients. *Others: Tonsillitis, meningitis, peritonitis, pharyngitis, cholangitis, pancreatitis, and sinusitis. Clinical interventions involving the Ceftazidime regimen and overall outcomes Intervention strategies for ceftazidime treatment included stopping treatment due to therapy completion in 276 (49.5%) scenarios, downgrading therapy in 175 (31.4%), and upgrading to another agent in 108 (19.4%). The majority of patients, including 511 (91.6%), were discharged as an overall outcome measure. Patient outcomes according to the Ceftazidime dosage and duration The relationships between patient outcomes and the dosage and duration of ceftazidime treatment were evaluated (Table 3). The median total daily dose of ceftazidime was the same for both discharged patients and those who died, with a median of 1 gram (IQR 1–2 g) for both groups (p = 0.709). The duration of ceftazidime treatment also showed no significant difference between the groups (p = 0.985), with both discharged and deceased patients having a median treatment duration of 4 days (IQR 3–6 days). Table 3Associations between patient outcomes, Ceftazidime dosage/duration, demographics, comorbidities, and infection types.VariableDischarged n = 511 (%)Died n = 47 (%)P valueTotal daily dose (gram, Median [IQR])1 (1–2)1 (1–2)0.709*Duration (days, Median [IQR])4 (3–6)4 (3–6)0.985* Maximum dose 3 g2 g– Minimum dose 0.1 g0.5 g– Age (years) < 1995 (18.6)1 (2.1)0.000†19–65289 (56.6)31 (66.0)0.212‡> 6595 (18.6)15 (31.9)0.028‡ Gender Male271 (53)26 (55.3)0.764‡Female240 (47)21 (44.7)– Hematological malignancies 286 (56.0)21 (44.7)0.137‡ Cardiovascular diseases 159 (31.1)20 (42.6)0.108‡ Solid malignancies 134 (26.2)22 (46.8)0.003‡ Diabetes mellitus 76 (14.9)13 (27.7)0.022‡ Kidney disease 60 (11.7)8 (17.0)0.290‡ Liver disease 25 (4.9)6 (12.8)0.024‡ Neutropenic fever 210 (41.1)11 (23.4)0.018‡ Pneumonia 173 (33.9)26 (55.3)0.003‡ Fever 137 (26.8)8 (17.0)0.143‡ Sepsis 59 (11.5)11 (23.4)0.019‡ Urinary tract infection 52 (10.2)4 (8.5)> 0.999† Soft tissue infection 17 (3.3)0 (0)0.384† Surgical prophylaxis 10 (2.0)0 (0)> 0.999† Bacteremia 6 (1.2)3 (6.4)0.033† Intra-abdominal infection 8 (1.6)0 (0)> 0.999† Others 14 (2.8)1 (2.1)> 0.999†* Mann–Whitney test.† Fisher’s exact test.‡ Pearson chi-square test. Associations between patient outcomes, Ceftazidime dosage/duration, demographics, comorbidities, and infection types. * Mann–Whitney test. † Fisher’s exact test. ‡ Pearson chi-square test. Associations between outcomes and patient demographics, comorbidities, and infection types The associations between the primary outcome and patient demographics, comorbidities, and types of infections were analysed in this study. The data revealed that younger age was significantly associated with better outcomes in terms of being discharged (p = 0.000). Among the comorbidities, solid malignancies (p = 0.003), diabetes mellitus (p = 0.022), and liver disease (p = 0.024) were significantly associated with increased mortality. The resistance rate to ceftazidime was also greater in isolates from patients with solid malignancies. However, no significant associations were observed between these comorbidities and pathogen resistance rates to ceftazidime. Neutropenic fever was more common among those discharged (41.1%) than among those who died (23.4%), with a significant p value of 0.018. Pneumonia was significantly more common in those who died (55.3%) than in those discharged (0.8%), with a p value of 0.003. This is illustrated in Table 3. A total of 87.4% of patients developed sepsis or septic shock during therapy. Among these patients, the mortality rate was 12.6%, which was significantly greater than that of patients who did not develop sepsis or septic shock (p < 0.05). The associations between the duration of hospital stay and the development of sepsis/septic shock among patients treated with ceftazidime are presented in Table 3. Antibiotics that were upgraded or downgraded from Ceftazidime In the present study, antibiotic interventions included both downgrading and upgrading treatments. Among the downgraded antibiotics, ciprofloxacin was the most common, constituting 12.2% of the cases; in contrast, piperacillin/tazobactam was the most common antibiotic among the upgraded antibiotics, constituting 11.8% of the cases. Notably, there were overlaps due to multiple upgraded or downgraded antibiotics for some patients, resulting in a total of 196 instances of downgraded antibiotics and 130 instances of upgraded antibiotics within the study population. For more details, please refer to Table 4. Table 4Antibiotics that were upgraded or downgraded from ceftazidime.Downgraded antibioticsN (%)Upgraded antibioticsN (%)Ciprofloxacin68(12.2)Piperacillin/Tazobactam66(11.8)Levofloxacin36(6.5)Vancomycin36(6.5)Amoxicillin clavulanate33(5.9)Meropenem11(2)Trimethoprim-sulfamethoxazole27(4.8)Amikacin9(1.6)Ceftriaxone8 (1.4)Colistin5 (0.9)Cefixime4(0.7)Tigecycline2(0.4)Azithromycin4 (0.7)Ertapenem1(0.2)Cefpodoxime3 (0.5)Cefdinir2 (0.4)Cefuroxime2 (0.4)Clindamycin2 (0.4)Doxycycline2 (0.4)Fosfomycin2 (0.4)Ampicillin1 (0.2)Penicillin IV1 (0.2)Metronidazole1 (0.2) Total 196(35.3) Total 130(23.4) *Overlap presented due to multiple upgraded or downgraded antibiotics for some patients. Antibiotics that were upgraded or downgraded from ceftazidime. *Overlap presented due to multiple upgraded or downgraded antibiotics for some patients. Isolated microorganism frequency and Ceftazidime susceptibility of patients treated with IV Ceftazidime We analysed culture results that were tested for ceftazidime and identified a total of 72 pathogens. The largest proportion of samples were urine samples (40.3%), followed by sputum samples (30.5%) and blood samples (16.7%). Other sources included wounds/tissues (7%), fluids (4.2%), and ear samples (1.4%). A microbiological profile study of patients who were treated with IV ceftazidime revealed that of the total patients, 72 patients had positive cultures tested for ceftazidime susceptibility. Among them, Escherichia coli was the most prevalent (36.1%), followed by Klebsiella pneumoniae at 19.4% and Pseudomonas aeruginosa at 11.1%. Additionally, the sensitivity of the isolates to ceftazidime was evaluated, with 38 (52.8%) isolates exhibiting sensitivity. The MIC of ceftazidime was 8 (interquartile range [IQR]: 1–64), as shown in Table 5. Table 5Isolated microorganism frequency and Ceftazidime susceptibility of patients treated with IV Ceftazidime.MicroorganismN (%)Sensitive to Ceftazidime n (%)Resistant to Ceftazidime n (%) Escherichia coli 26 (36.1)11(15.2)15(20.8) Klebsiella pneumoniae 14 (19.4)7 (9.7)7(9.7) Pseudomonas aeruginosa 8 (11.1)8(11.1)0(0.0) Acinetobacter baumannii 7 (9.7)2(2.8)5(6.9)Carbapenem-resistant K. pneumoniae4 (5.6)0(0.0)4(5.6) Serratia marcescens 4 (5.6)4(5.6)0(0.0) Enterobacter aerogenes 3 (4.2)3(4.2)0(0.0) Klebsiella oxytoca 2 (2.8)2(2.8)0(0.0) Morganella morganii 2 (2.8)0(0.0)2(2.8)ESBL-producing E. coli1 (1.4)0(0.0)1(1.4) Serratia odorifera 1 (1.4)1(1.4)0(0.0)Total72 (100)38(52.8)34 (47.2%)MIC (Median, IQR)8 (1–64) Isolated microorganism frequency and Ceftazidime susceptibility of patients treated with IV Ceftazidime. Table 6Hospital stay for patients who developed sepsis/septic shock.SourcePatients who developedsepsis/septic shockN = 488(87.4%)Patients who did not developedsepsis/septic shockN = 70 (12.5%)P value*Duration of hospital stay(median, IQR)5 (3–7)4 (3–6)0.562Maximum duration19 days15 daysMinimum duration2 days1 day*The P value was calculated via the Mann‒Whitney test. Hospital stay for patients who developed sepsis/septic shock. Duration of hospital stay (median, IQR) *The P value was calculated via the Mann‒Whitney test. Notably, among the isolated pathogens, E. coli presented the highest resistance rate to ceftazidime (47.2%). A closer analysis of pathogen resistance to ceftazidime revealed varying susceptibility levels. Among the Escherichia coli isolates, approximately 20.8% were resistant to ceftazidime. For Klebsiella pneumoniae, 9.7% of the isolates exhibited resistance. The sensitivities of the remaining organisms are displayed in Table 5. Discussion This retrospective observational study provided insights into the prescription practices of IV ceftazidime at a Palestinian tertiary care hospital, in addition to the microbiological profile of the isolated pathogens in patients treated with this agent. This study revealed that 68.5% of patients treated with ceftazidime were oncology patients. The most common indication for ceftazidime was neutropenic fever (39.6%), which is caused by chemotherapy-induced neutropenia17. Ceftazidime is used as a first-line antibiotic for treating high-risk febrile neutropenia patients because of its anti-Pseudomonas properties18–20. The second most common indication for ceftazidime was pneumonia (35.7%), which is in accordance with another study conducted in northern Ethiopia in which pneumonia was one of the most common indications (34.3%) 10. Furthermore, a case study in the United States revealed that 41% of patients treated with ceftazidime for pneumonia responded well to the treatment21. Major contributors to hospitalized patient mortality include sepsis and septic shock, which are linked to unacceptably high mortality and long-term morbidity22,23. In our study, 87.4% of the patients experienced sepsis or septic shock following ceftazidime administration during hospitalization. Septic shock was defined according to the Sepsis-3 criteria24, and all patients were followed until discharge or death. The highest risk groups included patients < 19 or > 65 years and those with underlying conditions such as solid malignancies, diabetes mellitus, or liver disease. Despite the high incidence of septic shock, in-hospital mortality remains relatively low (8.4%), likely due to early antibiotic initiation, specialized monitoring, and supportive care. Given the high rates of septic shock and ceftazidime resistance, empirical use in critically ill patients should be carefully considered, with culture-guided therapy prioritized. The microorganisms most frequently isolated from patients treated with ceftazidime were Escherichia coli (36.1%), Klebsiella pneumoniae (19.4%) and Pseudomonas aeruginosa (11.1%). Among these strains, Escherichia coli presented the highest resistance to ceftazidime, with approximately 20.8% of the isolates being resistant. Overall, 47.2% of the bacterial isolates in our study were resistant to ceftazidime, although only a minority of the patients were culture positive. These resistance rates are comparable to those reported in previous Palestinian studies (2022), where ceftazidime resistance reached 60% in Klebsiella pneumoniae isolates from oncology wards8,9. Similarly, in Lebanon (2019) and Jordan (2022), resistance rates ranging from 50 to 70% have been reported for key gram-negative organisms in intensive care patients and hospitalized patients, respectively5,6. This regional consistency highlights a shared AMR burden in the Eastern Mediterranean region and supports calls for region-specific empiric treatment guidelines. This finding aligns with previous regional studies that reported significant resistance among gram-negative bacteria. On the basis of the observed susceptibility patterns, ceftazidime may remain a reasonable empirical choice for certain infections, such as neutropenic fever, although caution is warranted given the overall high resistance rate. These results highlight the importance of considering patient-specific factors, such as medical history, allergies, underlying conditions, type of infection, disease severity, and local resistance patterns, when choosing empirical therapy25. Additionally, nearly one-fourth of the ceftazidime treatments were upgraded. These resistance rates are comparable to those reported in previous regional studies conducted between 2018 and 2022 among oncology and general hospitalized patients in Palestine, Lebanon, and Jordan, highlighting a shared AMR burden in the Eastern Mediterranean region. A Palestinian study reported that 60% of Klebsiella pneumoniae strains were resistant to ceftazidime, ciprofloxacin, and piperacillin/tazobactam​9. Similarly, 95.5% of Enterobacteriaceae in intra-abdominal infections are resistant26​. In contrast, a Lebanese study reported increased susceptibility of Acinetobacter baumannii (64.8%) to ceftazidime5. A study conducted in the Slovak Republic revealed that Pseudomonas aeruginosa is resistant to ceftazidime and cefepime by 7.7% 27. The high resistance rate to ceftazidime indicates the need for combination empiric therapy for patients with suspected resistant pathogens to increase therapeutic effectiveness until the final culture results are available. While ceftazidime has shown efficacy in treating severe cases, its use must be approached cautiously because of the increasing resistance rates observed in serious infections. As highlighted in this study, 47.2% of the isolates were resistant to ceftazidime, and nearly one-fourth of the treatments required escalation. This underscores the importance of careful antibiotic prescription practices to reduce the risk of resistance and treatment failure in critically ill patients. The clinical implications of these findings are particularly relevant in the Palestinian healthcare setting, where diagnostic delays, limited antimicrobial formularies, and frequent drug shortages necessitate empirical prescribing. The high ceftazidime resistance rate suggests that its continued use as a first-line agent—particularly in critically ill patients—may no longer be appropriate without culture guidance. This highlights the urgent need for structured ASPs to promote local antibiogram use, guide empiric choices, and support timely de-escalation or escalation. For example, a study from Thailand demonstrated that implementing an antimicrobial restriction system significantly increased appropriate carbapenem prescribing (from 38.3% to 55.0%) and reduced carbapenem expenditure by 36%, even without infectious disease consultation28. In resource-limited settings such as Palestine, ASPs are particularly critical owing to restricted drug formularies, frequent shortages of broad-spectrum antibiotics, limited access to rapid diagnostics, and reliance on empirical prescribing. Without ASP, inappropriate antibiotic use accelerates resistance and further limits therapeutic options. As part of ASP policies, therapeutic strategies also play a role in containing resistance and providing treatment options for difficult-to-treat pathogens, such as carbapenem-resistant K. pneumoniae, which was reported in 5.6% of the cases. Studying combination therapy vs. monotherapy efficacy for managing carbapenem-resistant pathogens and the 30-day mortality rate were the aims of a recent study, revealing that a combination therapy did not outperform monotherapy in terms of 30-day mortality or clinical and microbiological responses29. Recent studies further support the urgent need for tailored ASP interventions in the region. One study from the Eastern Mediterranean highlighted the high prevalence of ceftazidime-resistant pathogens, emphasizing the role of targeted interventions to curb resistance29. Additionally, another study discussed the successful implementation of ASP protocols, which significantly reduced resistance rates in tertiary care settings30. Another important aspect of ASP is optimizing the treatment duration. In terms of antimicrobial stewardship, reducing the duration of an antibiotic course may help lower antibiotic resistance. However, a previous study reported that long-course therapy had a lower 30-day mortality rate than short-course therapy did, comparable nephrotoxicity, and higher rates of clinical and microbiological response31. Interestingly, despite the high resistance rates, patients with neutropenic fever—the most common indication for ceftazidime—had relatively low mortality. This may reflect early initiation of antibiotics, specialized oncology care, and frequent reassessment. However, this outcome should not be interpreted as a justification for maintaining current empirical practices; rather, it underscores the need to revise local guidelines to reflect resistance patterns and infection severity. Specific strategies to enhance ASPs in our setting include the development and regular dissemination of local antibiograms, the implementation of preauthorization policies for high-risk antibiotics, and routine audit-and-feedback sessions involving pharmacists and infectious disease specialists. Educational initiatives targeting prescribers, particularly junior physicians and trainees, are also essential to promote rational prescribing habits. Ongoing education and awareness initiatives are vital for fostering responsible antibiotic prescribing practices. Implementing regular training sessions on ASPs, providing updated guidelines, and incorporating clinical decision support tools into daily practice can significantly reduce inappropriate antibiotic use. Engaging healthcare professionals through feedback mechanisms and multidisciplinary discussions is essential to sustain improvements in prescribing behavior and patient outcomes. Integrating clinical decision support tools into the electronic health records system may further optimize antibiotic selection and dosing. Several modifications and interventions for ceftazidime were carried out during the study period. Discontinuing ceftazidime was the major intervention (49.5%), followed by downgrading to another narrower spectrum agent (31.4%) and upgrading to another antibiotic (19.4%). Our findings also revealed that certain comorbidities were significantly associated with worse outcomes in patients receiving ceftazidime. Specifically, solid malignancies, diabetes mellitus, and liver disease are linked to relatively high mortality rates. These conditions may contribute to immune system dysfunction, delayed recovery, or a greater likelihood of severe infections and complications. This finding reinforces the need for careful patient risk stratification when selecting empirical antibiotic regimens. Among these comorbidities, solid malignancies had the strongest association with mortality, with 46.8% of patients with solid malignancies succumbing to their condition. This highlights the significant impact of malignancy-related immune suppression on patient outcomes. Future research and clinical implications On the basis of the findings of our study, some recommendations for future research and clinical implications are as follows: Preventive actions based on the spread of isolates can be derived. Whether ceftazidime prescription settings, such as frequency, administration techniques, and indications, are appropriate should be examined. Prospective analyses that examine the relevant parameters include randomized controlled trials. Preventive actions based on the spread of isolates can be derived. Whether ceftazidime prescription settings, such as frequency, administration techniques, and indications, are appropriate should be examined. Prospective analyses that examine the relevant parameters include randomized controlled trials. The effects of ceftazidime resistance on patient outcomes, including mortality, length of hospital stay, and treatment failure rate, were examined. Studies comparing the efficacy of different treatment approaches, such as targeted therapy versus empirical therapy, can yield valuable data for clinical decision-making and resource allocation. A program for ASP was created and assessed for a Palestinian tertiary care hospital. A successful plan requires a multidisciplinary approach involving physicians, microbiologists, pharmacists, and infection control specialists. The effects of ceftazidime resistance on patient outcomes, including mortality, length of hospital stay, and treatment failure rate, were examined. Studies comparing the efficacy of different treatment approaches, such as targeted therapy versus empirical therapy, can yield valuable data for clinical decision-making and resource allocation. A program for ASP was created and assessed for a Palestinian tertiary care hospital. A successful plan requires a multidisciplinary approach involving physicians, microbiologists, pharmacists, and infection control specialists. Patient and family participation should be promoted to better understand patients’ preferences regarding potential complications. Incorporating shared decision-making principles and patient-reported outcomes into clinical practice can decrease unnecessary antibiotic use and increase treatment adherence and satisfaction. Patient and family participation should be promoted to better understand patients’ preferences regarding potential complications. Incorporating shared decision-making principles and patient-reported outcomes into clinical practice can decrease unnecessary antibiotic use and increase treatment adherence and satisfaction. Strengths and limitations This study is the first of its kind in Palestine, addressing the topic of clinical epidemiology and microbiology profiling of patients receiving ceftazidime treatment at a tertiary care hospital. This study provides important baseline data to inform empirical antibiotic therapy in the region, particularly in the absence of national surveillance systems. Additionally, the study benefited from its large sample size, comprising data from 558 patients. The retrospective observational nature of this study raises the risk of incomplete or missing information, particularly concerning the susceptibility pattern of the pathogens. Because the data were extracted from past medical records rather than being prospectively collected, some variables may have been underreported. Additionally, causal relationships between resistance and outcomes cannot be inferred from this design. The quality of medical records determines the accuracy and completeness of the data. For example, adverse effects and renal dose adjustments were not feasible. Second, the study’s application to other situations or populations may have been limited by the fact that it was carried out at a single tertiary care hospital in Palestine. Third, the study’s timeframe from June 2021 to June 2023 may not have adequately captured variations in prescription practices and resistance patterns over different periods. Another limitation is that the factors leading to modifications in ceftazidime management have not been studied specifically. Finally, one of the key limitations of this study is that while we provided data on the overall rate of ceftazidime resistance among isolated bacteria, we did not include a detailed analysis of specific resistance mechanisms, such as the rates of ESBLs or AmpC beta-lactamases. This was due to the study’s scope and resource constraints, which prevented a more in-depth investigation into these mechanisms. Future studies should investigate specific resistance mechanisms, such as extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and carbapenemases, via molecular techniques to better understand local resistance patterns. In addition, the impact of ongoing armed conflict and political instability in Palestine presents unique challenges for the ASP. Medication shortages, restricted access to newer antimicrobials, and limitations in diagnostic infrastructure all hinder the timely initiation of appropriate antimicrobial therapy. Future research is necessary to explore these specific resistance patterns to better inform antimicrobial therapy and resistance management strategies. This study offers important baseline data that can guide future surveillance and policy efforts in Palestine, especially in the absence of a national antibiogram or real-time resistance tracking system. Conclusions This study investigated the use and prescription practices of ceftazidime, especially in oncology settings, in a tertiary care hospital. The increasing resistance rate to ceftazidime—particularly among Escherichia coli and Klebsiella pneumoniae—poses a major challenge for empirical therapy, especially in critically ill patients, and underscores the urgent need for ASP adoption in resource-limited settings. Patient age, comorbidities, and infection type significantly influence outcomes, underscoring the need for careful risk stratification. These findings highlight the importance of locally adapted treatment guidelines, routine microbiological surveillance, and further research to optimize antibiotic use and improve patient outcomes. Future efforts should focus on developing national antibiotic stewardship frameworks and establishing regular antibiogram reporting to guide empirical antibiotic therapy. Acknowledgements We express our gratitude to the Infectious Disease Department and all other medical departments at An-Najah National University Hospital for their invaluable assistance in locating patient data and meticulously reviewing medical records. Abbreviations Antimicrobial resistance Antibiotic stewardship program Twice daily Extended-spectrum beta-lactamases International business machines Interquartile range Institutional Review Board Intravenous Minimum inhibitory concentration An-Najah National University Hospital Once daily Four times daily Statistical Package for Social Sciences Three times daily Author contributions The first draft of the manuscript was written by S.A., L.B., and A.Y., who also collected the data and performed the analysis. A.S. and A.A. provided logistical support, designed the study, and contributed to the preparation of the final manuscript. D.A. thoroughly reviewed the manuscript to improve its intellectual content, interpreted the data, and made revisions to address all concerns raised by the new reviewers. S.H.Z., B.M.A., and S.W.A. conceptualized and designed the study, analysed and coordinated the data, supervised the field study, critically reviewed the manuscript, interpreted the results, and contributed to the final version of the manuscript. All the authors approved the final manuscript. Data availability The data from our surveillance are not available in the public domain owing to privacy and ethical restrictions, but anyone interested in using the data for scientific purposes is free to request permission from the corresponding authors. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Samah W. Al-Jabi, Email: samahjabi@yahoo.com Sa’ed H. Zyoud, Email: saedzyoud@yahoo.com References Associated Data Data Availability Statement The data from our surveillance are not available in the public domain owing to privacy and ethical restrictions, but anyone interested in using the data for scientific purposes is free to request permission from the corresponding authors.